Keros Therapeutics, Inc.
NASDAQ:KROS
16.81 (USD) • At close December 26, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0.151 | 0 | 20.1 | 0 | 10 | 10 |
| Cost of Revenue
| 0.815 | 1.615 | 0.898 | 0.605 | 17.348 | 10.111 |
| Gross Profit
| -0.664 | -1.615 | 19.202 | -0.605 | -7.348 | -0.111 |
| Gross Profit Ratio
| -4.397 | 0 | 0.955 | 0 | -0.735 | -0.011 |
| Reseach & Development Expenses
| 135.258 | 87.265 | 55.143 | 33.86 | 17.379 | 10.111 |
| General & Administrative Expenses
| 34.834 | 27.525 | 21.33 | 12.797 | 3.184 | 1.58 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 34.834 | 27.525 | 21.33 | 12.797 | 3.184 | 1.58 |
| Other Expenses
| 0 | -7.081 | -0.356 | -2.46 | -0.558 | 0.237 |
| Operating Expenses
| 170.092 | 107.709 | 76.473 | 44.197 | 20.005 | 11.321 |
| Operating Income
| -169.941 | -114.79 | -56.373 | -46.657 | -10.563 | -1.691 |
| Operating Income Ratio
| -1,125.437 | 0 | -2.805 | 0 | -1.056 | -0.169 |
| Total Other Income Expenses Net
| 16.949 | 10.111 | -0.36 | 1.124 | -1.773 | 0.613 |
| Income Before Tax
| -152.992 | -104.679 | -56.733 | -45.533 | -12.336 | -1.078 |
| Income Before Tax Ratio
| -1,013.192 | 0 | -2.823 | 0 | -1.234 | -0.108 |
| Income Tax Expense
| 0 | 0.001 | 2.011 | -0.172 | 0.008 | 0.257 |
| Net Income
| -152.992 | -104.68 | -58.744 | -45.361 | -12.344 | -1.335 |
| Net Income Ratio
| -1,013.192 | 0 | -2.923 | 0 | -1.234 | -0.134 |
| EPS
| -5.2 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| EPS Diluted
| -5.2 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| EBITDA
| -152.177 | -103.063 | -56.373 | -44.922 | -11.89 | -0.774 |
| EBITDA Ratio
| -1,007.795 | 0 | -2.822 | 0 | -0.98 | -0.117 |